Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Bladder (Late Stage^), 2017-2021

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Count

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 2.4 (2.3, 2.4) N/A 9,471 12.6
District of Columbia 6 2.8 (2.3, 3.5) 8 (1, 46) 18 19.8
Alaska 6 2.9 (2.4, 3.6) 3 (1, 42) 21 15.7
Wyoming 6 2.9 (2.4, 3.6) 2 (1, 42) 22 14.6
North Dakota 6 2.7 (2.2, 3.2) 14 (1, 47) 24 13.6
Vermont 6 2.6 (2.2, 3.1) 17 (1, 47) 26 12.2
South Dakota 6 2.8 (2.3, 3.3) 9 (1, 40) 31 13.5
Delaware 6 2.2 (1.9, 2.6) 37 (7, 50) 31 10.3
Hawaii 3 1.7 (1.4, 2.0) 50 (40, 50) 35 12.7
Rhode Island 6 2.5 (2.1, 2.9) 21 (2, 47) 36 10.5
Puerto Rico 6 0.8 (0.7, 0.9) N/A 37 8.3
Montana 6 2.7 (2.3, 3.1) 10 (1, 40) 40 12.3
New Mexico 3 1.9 (1.6, 2.1) 49 (36, 50) 53 13.9
Nebraska 6 2.3 (2.0, 2.6) 34 (12, 49) 53 11.7
Utah 3 1.9 (1.7, 2.2) 47 (32, 50) 54 11.5
Idaho 3 2.6 (2.3, 2.9) 19 (2, 41) 56 12.5
New Hampshire 6 2.9 (2.6, 3.3) 4 (1, 28) 57 11.4
Maine 6 3.3 (3.0, 3.7) 1 (1, 9) 72 12.8
Mississippi 6 2.0 (1.8, 2.3) 43 (27, 50) 74 12.0
West Virginia 6 2.8 (2.5, 3.1) 7 (1, 28) 76 13.4
Nevada 6 2.1 (1.9, 2.3) 41 (23, 49) 78 11.9
Kansas 6 2.3 (2.1, 2.5) 32 (13, 47) 82 11.3
Arkansas 6 2.2 (2.0, 2.4) 40 (21, 49) 84 11.9
Iowa 3 2.6 (2.4, 2.9) 15 (3, 31) 111 12.1
Oklahoma 6 2.3 (2.1, 2.5) 29 (13, 43) 111 13.0
Louisiana 3 2.2 (2.0, 2.4) 39 (23, 47) 123 12.3
Connecticut 3 2.6 (2.4, 2.8) 18 (4, 33) 123 10.9
Alabama 6 2.0 (1.8, 2.1) 46 (34, 50) 129 11.8
Colorado 6 2.1 (1.9, 2.2) 42 (31, 49) 131 12.0
Oregon 6 2.4 (2.2, 2.6) 27 (11, 40) 135 12.5
South Carolina 6 2.2 (2.0, 2.4) 38 (24, 47) 147 13.0
Kentucky 3 2.7 (2.5, 2.9) 11 (3, 27) 153 12.5
Maryland 6 2.3 (2.1, 2.4) 35 (21, 44) 170 14.7
Minnesota 6 2.5 (2.4, 2.7) 20 (7, 33) 175 11.9
Arizona 6 1.9 (1.8, 2.0) 48 (39, 50) 180 10.7
Missouri 6 2.5 (2.3, 2.6) 24 (10, 37) 196 13.4
Tennessee 6 2.3 (2.2, 2.5) 30 (17, 41) 200 12.2
Wisconsin 6 2.7 (2.5, 2.9) 13 (4, 26) 208 12.5
Washington 5 2.4 (2.3, 2.5) 28 (14, 39) 217 12.1
Virginia 6 2.5 (2.3, 2.6) 26 (12, 35) 254 14.3
Georgia 3 2.3 (2.1, 2.4) 33 (23, 42) 261 12.5
New Jersey 3 2.3 (2.2, 2.4) 31 (20, 41) 271 10.8
North Carolina 6 2.5 (2.3, 2.6) 25 (12, 34) 320 12.9
Michigan 6 2.6 (2.5, 2.7) 16 (6, 27) 353 13.0
Illinois 3 2.7 (2.6, 2.8) 12 (5, 21) 422 13.8
Ohio 6 2.9 (2.8, 3.0) 6 (2, 13) 447 13.4
Pennsylvania 6 2.9 (2.8, 3.0) 5 (2, 12) 525 13.5
New York 3 2.2 (2.2, 2.3) 36 (27, 42) 578 10.8
Texas 3 2.0 (1.9, 2.1) 44 (38, 49) 578 13.3
Florida 6 2.5 (2.4, 2.6) 22 (14, 30) 804 13.0
California 3 2.0 (1.9, 2.1) 45 (40, 49) 882 12.9
Indiana 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 12/07/2024 10:47 pm.

State Cancer Registries may provide more current or more local data.

Data cannot be shown for the following areas. For more information on what areas are suppressed or not available, please refer to the table.
Indiana

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
Source: SEER and NPCR data. For more specific information please see the table.

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top